These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

716 related articles for article (PubMed ID: 18215105)

  • 21. Inhibition of the mammalian target of rapamycin (mTOR) in advanced pancreatic cancer: results of two phase II studies.
    Javle MM; Shroff RT; Xiong H; Varadhachary GA; Fogelman D; Reddy SA; Davis D; Zhang Y; Wolff RA; Abbruzzese JL
    BMC Cancer; 2010 Jul; 10():368. PubMed ID: 20630061
    [TBL] [Abstract][Full Text] [Related]  

  • 22. PI3K/AKT/mTOR pathway is activated after imatinib secondary resistance in gastrointestinal stromal tumors (GISTs).
    Li J; Dang Y; Gao J; Li Y; Zou J; Shen L
    Med Oncol; 2015 Apr; 32(4):111. PubMed ID: 25757539
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Temsirolimus in advanced leiomyosarcomas: patterns of response and correlation with the activation of the mammalian target of rapamycin pathway.
    Italiano A; Kind M; Stoeckle E; Jones N; Coindre JM; Bui B
    Anticancer Drugs; 2011 Jun; 22(5):463-7. PubMed ID: 21301319
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mammalian target of rapamycin inhibitors as possible adjuvant therapy for microscopic residual disease in head and neck squamous cell cancer.
    Nathan CO; Amirghahari N; Rong X; Giordano T; Sibley D; Nordberg M; Glass J; Agarwal A; Caldito G
    Cancer Res; 2007 Mar; 67(5):2160-8. PubMed ID: 17332346
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Inhibitors of mTOR reverse doxorubicin resistance conferred by PTEN status in prostate cancer cells.
    Grünwald V; DeGraffenried L; Russel D; Friedrichs WE; Ray RB; Hidalgo M
    Cancer Res; 2002 Nov; 62(21):6141-5. PubMed ID: 12414639
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR.
    Neshat MS; Mellinghoff IK; Tran C; Stiles B; Thomas G; Petersen R; Frost P; Gibbons JJ; Wu H; Sawyers CL
    Proc Natl Acad Sci U S A; 2001 Aug; 98(18):10314-9. PubMed ID: 11504908
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phase I study of temsirolimus in pediatric patients with recurrent/refractory solid tumors.
    Spunt SL; Grupp SA; Vik TA; Santana VM; Greenblatt DJ; Clancy J; Berkenblit A; Krygowski M; Ananthakrishnan R; Boni JP; Gilbertson RJ
    J Clin Oncol; 2011 Jul; 29(21):2933-40. PubMed ID: 21690471
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Akt demoted in glioblastoma.
    Vogt PK; Hart JR
    Sci Signal; 2009 Apr; 2(67):pe26. PubMed ID: 19383977
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A novel PTEN-dependent link to ubiquitination controls FLIPS stability and TRAIL sensitivity in glioblastoma multiforme.
    Panner A; Crane CA; Weng C; Feletti A; Parsa AT; Pieper RO
    Cancer Res; 2009 Oct; 69(20):7911-6. PubMed ID: 19808964
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The mTOR kinase inhibitors, CC214-1 and CC214-2, preferentially block the growth of EGFRvIII-activated glioblastomas.
    Gini B; Zanca C; Guo D; Matsutani T; Masui K; Ikegami S; Yang H; Nathanson D; Villa GR; Shackelford D; Zhu S; Tanaka K; Babic I; Akhavan D; Lin K; Assuncao A; Gu Y; Bonetti B; Mortensen DS; Xu S; Raymon HK; Cavenee WK; Furnari FB; James CD; Kroemer G; Heath JR; Hege K; Chopra R; Cloughesy TF; Mischel PS
    Clin Cancer Res; 2013 Oct; 19(20):5722-32. PubMed ID: 24030701
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Unique, highly proliferative growth phenotype expressed by embryonic and neointimal smooth muscle cells is driven by constitutive Akt, mTOR, and p70S6K signaling and is actively repressed by PTEN.
    Mourani PM; Garl PJ; Wenzlau JM; Carpenter TC; Stenmark KR; Weiser-Evans MC
    Circulation; 2004 Mar; 109(10):1299-306. PubMed ID: 14993145
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of the mammalian target of rapamycin inhibitor CCI-779 used alone or with chemotherapy on human prostate cancer cells and xenografts.
    Wu L; Birle DC; Tannock IF
    Cancer Res; 2005 Apr; 65(7):2825-31. PubMed ID: 15805283
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Carnosine inhibits glioblastoma growth independent from PI3K/Akt/mTOR signaling.
    Oppermann H; Faust H; Yamanishi U; Meixensberger J; Gaunitz F
    PLoS One; 2019; 14(6):e0218972. PubMed ID: 31247000
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Implications for immunotherapy of tumor-mediated T-cell apoptosis associated with loss of the tumor suppressor PTEN in glioblastoma.
    Waldron JS; Yang I; Han S; Tihan T; Sughrue ME; Mills SA; Pieper RO; Parsa AT
    J Clin Neurosci; 2010 Dec; 17(12):1543-7. PubMed ID: 20822910
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition.
    Sun SY; Rosenberg LM; Wang X; Zhou Z; Yue P; Fu H; Khuri FR
    Cancer Res; 2005 Aug; 65(16):7052-8. PubMed ID: 16103051
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Enhanced sensitivity of multiple myeloma cells containing PTEN mutations to CCI-779.
    Shi Y; Gera J; Hu L; Hsu JH; Bookstein R; Li W; Lichtenstein A
    Cancer Res; 2002 Sep; 62(17):5027-34. PubMed ID: 12208757
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Perifosine and CCI 779 co-operate to induce cell death and decrease proliferation in PTEN-intact and PTEN-deficient PDGF-driven murine glioblastoma.
    Pitter KL; Galbán CJ; Galbán S; Tehrani OS; Li F; Charles N; Bradbury MS; Becher OJ; Chenevert TL; Rehemtulla A; Ross BD; Holland EC; Hambardzumyan D
    PLoS One; 2011 Jan; 6(1):e14545. PubMed ID: 21267448
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Recent advances in the use of PI3K inhibitors for glioblastoma multiforme: current preclinical and clinical development.
    Zhao HF; Wang J; Shao W; Wu CP; Chen ZP; To ST; Li WP
    Mol Cancer; 2017 Jun; 16(1):100. PubMed ID: 28592260
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Anti-Tumor Effects of Sodium Meta-Arsenite in Glioblastoma Cells with Higher Akt Activities.
    Lee EJ; Sung JY; Koo KH; Park JB; Kim DH; Shim J; Lee CH; Park J; Kim YN
    Int J Mol Sci; 2020 Nov; 21(23):. PubMed ID: 33256086
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dual mTORC1/2 blockade inhibits glioblastoma brain tumor initiating cells in vitro and in vivo and synergizes with temozolomide to increase orthotopic xenograft survival.
    Luchman HA; Stechishin OD; Nguyen SA; Lun XQ; Cairncross JG; Weiss S
    Clin Cancer Res; 2014 Nov; 20(22):5756-67. PubMed ID: 25316808
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 36.